NCT07013643 - A Study to Investigate the Effect of AZD6234 and a Combination of AZD9550 and AZD6234 on Pharmacokinetics of Combined Oral Contraceptive Ethinyl Estradiol/Levonorgestrel in Healthy Female Participants Living With Overweight or Obesity | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 4, 2025

Primary Completion Date

January 7, 2026

Study Completion Date

January 7, 2026

Conditions

Healthy Participants

Interventions

DRUG

AZD6234

AZD6234 will be administered as a subcutaneous injection in the abdomen.

DRUG

Ethinyl estradiol/Levonorgestrel (EE/LEVO)

EE/LEVO will be administered as combined oral tablets.

DRUG

Acetaminophen (APAP)

APAP will be administered orally as a solution.

DRUG

AZD9550

AZD9550 will be administered as a subcutaneous injection in the abdomen.

Trial Locations (2)

RECRUITING

Research Site, Brooklyn

RECRUITING

Research Site, Glendale